- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00158600
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease
April 6, 2015 updated by: Genzyme, a Sanofi Company
Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Myozyme in Patients With Late-Onset Pompe Disease.
Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA).
Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes.
In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function.
The overall objective is to evaluate the safety, efficacy, and pharmacokinetics (PK) of alglucosidase alfa treatment in patients with late-onset Pompe disease as compared to placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
90
Phase
- Phase 3
Expanded Access
Approved for sale to the public.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75651
- Groupe Hospitalier Pitie-Salpetriere
-
-
-
-
-
Rotterdam, Netherlands, 3000 CB
- Sophia Children's Hospital, Erasmus MC
-
Rotterdam, Netherlands, 3015 GD
- Erasmus Medical Centre Rotterdam
-
-
-
-
California
-
Beverly Hills, California, United States, 90211
- Tower Hematology Oncology Medical Group
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University Medical Center
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh, Dept. of Neurology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient must provide signed, informed consent prior to performing any study-related procedures.
- Patient must have a diagnosis of Pompe disease based on deficient endogenous GAA activity in cultured skin fibroblasts of less than or equal to 40% of the normal mean of the testing laboratory and 2 confirmed GAA gene mutations;
- Patient must be greater than or equal to 8 years of age at the time of enrollment;
- Patient must be able to ambulate 40 meters (approximately 130 feet) in 6 minutes on each test performed on two consecutive days (use of assistive devices such as a walker, cane, or crutches, is permitted);
- Patient must have an FVC of greater than or equal to 30% and < 80% predicted in the upright position;
- Patient must have a postural drop in FVC (liters) of at least 10% from the upright to the supine position;
- Patient must have proximal muscle weakness in the lower limbs based on unilateral QMT of the knee extensors defined as < 80% of the predicted value based on age, gender and body size
- Patient must be able to tolerate pulmonary function testing (PFT) and muscle testing in the supine position;
- Patient must have testable muscle in bilateral knee flexors and knee extensors, and testable muscle in bilateral elbow flexors and elbow extensors;
- Patient must be able to provide reproducible muscle and pulmonary function test results;
- Patient (and patient's legal guardian if patient is < 18 years of age) must have the ability to comply with the clinical protocol;
- A female patient of childbearing potential must have a negative pregnancy test (urine) at Baseline. Note: All female patients of childbearing potential and sexually mature males must use a medically accepted method of contraception throughout the study.
Exclusion Criteria:
- Patient requires the use of invasive ventilatory support;
- Patient requires the use of noninvasive ventilatory support while awake and in an upright position;
- Patient has received enzyme replacement therapy with GAA from any source;
- Patient has used an investigational product within 30 days prior to study enrollment, or is currently enrolled in another study which involves clinical evaluations, unless prior approval is given by Genzyme;
- Patient has a major congenital anomaly, medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: alglucosidase alfa
Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
|
IV infusion of 20mg/kg; qow for 78 weeks.
Other Names:
|
Placebo Comparator: Placebo
Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
|
Placebo Comparator; qow for 78 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summary of Patients Reporting Treatment-Emergent Adverse Events
Time Frame: weeks 0-78
|
Overall safety summary of patients experiencing Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, and Infusion Associated Reactions (IARs).
Summary is based on Treatment-emergent AEs (TEAEs), defined as AEs that occurred following the initiation of study treatment, i.e., alglucosidase alfa or placebo.
|
weeks 0-78
|
Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From Baseline
Time Frame: weeks 0, 78
|
Mean distance walked gives an indication of functional endurance.
The greater the distance, the greater the endurance.
Mean values of distance walked in a six-minute walk test are offered for baseline, week 78 (or last available observation), and the mean change from baseline (at week 78 or last available post-baseline observation).
|
weeks 0, 78
|
Percent of Predicted Forced Vital Capacity (FVC)
Time Frame: weeks 0, 78
|
Forced vital capacity is a standard pulmonary function test used to quantify respiratory muscle weakness.
Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters.
Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity.
Percent of predicted FVC = (observed value)/(predicted value) * 100%.
|
weeks 0, 78
|
Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC)
Time Frame: weeks 0, 12 and 52
|
Area under the plasma concentration versus time curve from time zero (pre-dose) to 16 hours after the end of infusion.
Blood sample time points were 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion).
Pooled figures combine the values for the three timeframes.
|
weeks 0, 12 and 52
|
Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration(Cmax)
Time Frame: weeks 0, 12, 52
|
Maximum plasma concentration observed in blood samples taken at the following time points: 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion).
Pooled figures combine the values for the three timeframes.
|
weeks 0, 12, 52
|
Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax)
Time Frame: weeks 0, 12, 52
|
Time to maximum plasma concentration observed in blood samples taken at the following time points: 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion).
Pooled figures combine the values for the three timeframes.
|
weeks 0, 12, 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Predicted Proximal Muscle Strength of the Lower Limbs as Measured by Quantitative Muscle Testing (QMT)
Time Frame: weeks 0, 78
|
Quantitative muscle testing (QMT) is a standardized system to measure muscle force production during maximal voluntary isometric contraction.
QMT data were collected directly from sensors into laptop computers.
Predicted normal values for QMT are based on a formula using sex, age and body mass index of a person, and is an estimate of healthy muscle force.
Percent of predicted QMT = (observed value)/(predicted value) * 100%.
The QMT Leg Score is the average of the bilateral means for percent predicted knee flexors and extensors.
A value of 100% indicates 'normal' muscle strength.
|
weeks 0, 78
|
Health-related Quality of Life Survey Values Related to Physical Components as Measured by the Medical Outcomes Study (MOS) Short Form-36 Health Survey
Time Frame: weeks 0, 78
|
The Medical Outcomes Study Short Form (MOS SF)-36 questionnaire consists of 36 items grouped into 8 domains designed to assess generic health-related quality of life in healthy and ill adult populations.
Physical Component Scores (PCS) report the four domains of physical functioning, role-physical, bodily pain, and general health.
Higher scores are associated with better quality of life.
All questions are scored on a scale from 0 to 100, with 100 representing the highest level of functioning possible.
The PCS scores are reported.
|
weeks 0, 78
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Forsha D, Li JS, Smith PB, van der Ploeg AT, Kishnani P, Pasquali SK; Late-Onset Treatment Study Investigators. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Genet Med. 2011 Jul;13(7):625-31. doi: 10.1097/GIM.0b013e3182142966.
- van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010 Apr 15;362(15):1396-406. doi: 10.1056/NEJMoa0909859.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2005
Primary Completion (Actual)
September 1, 2007
Study Completion (Actual)
September 1, 2007
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 8, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
April 28, 2015
Last Update Submitted That Met QC Criteria
April 6, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Nutrition Disorders
- Genetic Diseases, Inborn
- Malnutrition
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Lysosomal Storage Diseases, Nervous System
- Disease
- Deficiency Diseases
- Glycogen Storage Disease Type II
- Glycogen Storage Disease
Other Study ID Numbers
- AGLU02704
- 2005-002759-42 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pompe Disease (Late-onset)
-
University of Erlangen-Nürnberg Medical SchoolRecruitingPompe Disease (Late-onset) | Pompe Disease | Pompe's Disease Juvenile Onset | Pompe Disease Infantile-OnsetGermany
-
Indiana UniversityNational Institute on Aging (NIA)RecruitingDementia | Alzheimer Disease, Late OnsetUnited States
-
Ohio State UniversityCompletedAlzheimer Disease, Late OnsetUnited States
-
NeuroEM Therapeutics, Inc.University of South Florida Health / Byrd Alzheimer's InstituteUnknownAlzheimer Disease | Alzheimer Disease, Late OnsetUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknownAlzheimer Disease, Late OnsetBelgium
-
University of MinnesotaMayo Clinic; National Institute on Aging (NIA); University of St ThomasCompletedAlzheimer's Disease, Late OnsetUnited States
-
NeuroEM Therapeutics, Inc.Invicro, Boston; Byrd Alzheimer's Institute, University of South Florida; University... and other collaboratorsCompletedAlzheimer Disease | Alzheimer Disease, Late OnsetUnited States
-
Federal University of Minas GeraisCompletedAlzheimer Disease, Late Onset
-
IRCCS Centro San Giovanni di Dio FatebenefratelliI.R.C.C.S. Fondazione Santa Lucia; Ministero della Salute, ItalyRecruitingAlzheimer Disease | Alzheimer Disease, Late Onset | Cognitive DeteriorationItaly
-
Tamir Ben-HurHebrew University of JerusalemEnrolling by invitationAlzheimer Disease, Late OnsetIsrael
Clinical Trials on alglucosidase alfa
-
Taipei Veterans General Hospital, TaiwanNot yet recruitingGlycogen Storage Disease Type II
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Pompe Disease Infantile-OnsetUnited States, France, South Africa
-
Genzyme, a Sanofi CompanyApproved for marketingGlycogen Storage Disease Type II | Glycogenosis 2
-
Genzyme, a Sanofi CompanyApproved for marketingGlycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)United States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIChina
-
Genzyme, a Sanofi CompanyCompletedPompe Disease | Glycogen Storage Disease Type II (GSD II)United States, Russian Federation, United Kingdom, Bulgaria, India, Ukraine
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States, Israel, France, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, Taiwan, Israel, United Kingdom, France
-
Genzyme, a Sanofi CompanyTerminatedGlycogenosis 2 | Glycogen Storage Disease Type II (GSD II) | Acid Maltase Deficiency | Pompe Disease (Infantile-Onset)United States, Taiwan, Germany